As the VEGF signaling pathway was enriched in the ZNF385A- and ZNF346-high groups, we predicted the chemotherapeutic response of sorafenib for each sample, based on the Genomics of Drug Sensitivity in the Cancer (GDSC) database. This evidence concerns the gene ZNF385A and cancer.